20-F/A: BioLineRx Amends 20-F for Auditor Consent Correction

BioLineRx Ltd. filed an amended annual report on Form 20-F/A to correct the date in its auditor's consent and refile executive certifications.

Summary

• BioLineRx Ltd. filed an Amendment No. 1 to its Annual Report on Form 20-F for the fiscal year ended December 31, 2025.
• The primary purpose of this amendment is to revise the consent of Kesselman & Kesselman (PwC), which referenced an incorrect date in the original filing.
• A new consent from PwC, dated March 27, 2026, has been filed as an exhibit.
• New certifications by the principal executive officer (CEO) and principal financial officer (CFO) are also being filed as Exhibits 12.1, 12.2, 13.1, and 13.2.
• This amendment explicitly states that it does not reflect events occurring after the original filing date and does not modify or update any other disclosures in the Original Report, except as described.
• The company reported 2,610,814,390 ordinary shares outstanding as of March 8, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is an administrative correction to ensure compliance and accuracy, rather than an announcement of operational or financial performance, thus having no direct positive or negative impact on the company's fundamental outlook.

Positives

• The company is actively addressing and correcting administrative errors, demonstrating a commitment to regulatory compliance and accurate financial reporting.
• The refiling of CEO and CFO certifications under Sarbanes-Oxley Act Sections 302 and 906 reinforces management's accountability for the integrity of financial statements and internal controls.

Negatives

• The initial error in the auditor's consent date indicates a minor administrative oversight in the original filing process.

Risks

• No new specific risks are introduced or highlighted in this administrative amendment. The general risks associated with the accuracy of financial reporting are implicitly addressed by the correction.

Future Outlook

This administrative amendment does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Philip A. Serlin, Chief Executive Officer, certified that the report does not contain any untrue statement of a material fact or omit a material fact, and that financial statements fairly present the company's condition, results, and cash flows.
• Mali Zeevi, Chief Financial Officer, provided similar certifications regarding the accuracy of the report and fair presentation of financial information.
• Both officers certified responsibility for establishing and maintaining disclosure controls and internal control over financial reporting, and disclosed any significant deficiencies, material weaknesses, or fraud to auditors and the audit committee.

Industry Context

StockSavvy.ai notes that such administrative amendments are common in regulatory reporting and reflect ongoing compliance efforts rather than strategic shifts. This filing is a procedural correction to ensure the accuracy of previously submitted documents, which is a standard practice in maintaining robust financial reporting integrity within the biotechnology industry.

Comparison to Industry Standards

• This filing is an administrative correction and does not contain operational or financial results that can be directly compared to industry benchmarks or specific competitor projects.
• The act of filing an amendment to correct an error and refile certifications aligns with best practices for regulatory compliance and corporate governance across publicly traded companies, including those in the biotech sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Ensures the accuracy and compliance of the company's annual report, providing reliable information for investment decisions.
• Regulatory Bodies: Demonstrates the company's adherence to SEC reporting requirements and commitment to correcting errors promptly.
• Auditors: The corrected consent clarifies the auditor's report date, maintaining proper documentation.

Next Steps

• No specific future actions, events, or milestones are mentioned in this administrative amendment beyond the filing itself.

Key Dates

Keywords

BioLineRx, 20-F/A, SEC filing, annual report amendment, auditor consent, financial reporting, corporate governance, Sarbanes-Oxley, PwC